MSB 0.00% $1.09 mesoblast limited

banter and General Discussion, page-9364

  1. 1,432 Posts.
    lightbulb Created with Sketch. 3133
    Hi @irenekwshiu,

    I don't know the answer to your question. However, I take from Dr Lightner's dissociation from Direct Biologics inside roughly 12 months of commencement as CMO that her first contact with biotech's corporate private sector didn't work out exactly as she'd anticipated. Of course, there are any number of possible personal and business reasons why that may have occurred. Also her Linked In page seems to suggest she was engaged as CMO at Direct Biologics in Texas months before the announcement on Feb 15, 2023, which is weird, and then started on-site at Scripps in California within a further 3 months, which is also weird. Anyhow, it may well be that there is potential for a future association of MSB with Dr Lightner.

    However, if I were CEO Itescu (and I'm not) then at the moment I'd be more concerned with the 'Unknown' recruitment status showing on clinicaltrials.gov's website for NCT04548583 and NCT04543994.

    If that's anything to do with Dr Lightner - and IMO it's hard to see it as not involving her in some way (recall she remains the registered Principal Investigator i.e. person responsible for submitting information about those clinical studies to ClinicalTrials.gov and updating that information) - then I wouldn't be in much of a hurry to see that association move anyplace anytime soon.

    Cheers
    GLTA(LT)H

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.09
Change
0.000(0.00%)
Mkt cap ! $1.244B
Open High Low Value Volume
$1.10 $1.12 $1.08 $1.355M 1.235M

Buyers (Bids)

No. Vol. Price($)
11 60918 $1.09
 

Sellers (Offers)

Price($) Vol. No.
$1.09 27170 10
View Market Depth
Last trade - 10.41am 18/06/2024 (20 minute delay) ?
Last
$1.08
  Change
0.000 ( 0.76 %)
Open High Low Volume
$1.10 $1.12 $1.08 208946
Last updated 11.00am 18/06/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.